Status:
RECRUITING
Biomarkers Predictive of Thymic Evolution and Therapeutic Response at 2 Years in Patients With a First Psychotic Episode
Lead Sponsor:
University Hospital, Brest
Conditions:
First-episode Psychosis
Eligibility:
All Genders
15-30 years
Phase:
NA
Brief Summary
Psychosis is a severe, common, and disabling psychological disorder. An epidemiological study conducted in England reported an incidence of 34 new cases per 100,000 person-years, with a peak between 1...
Eligibility Criteria
Inclusion
- Patient with a first episode of psychosis,
- Aged between 15 and 30 years,
- Able to consent and having signed a consent form (parental consent for minors).
Exclusion
- Introduction or increase of antipsychotic and/or antidepressant and/or thymoregulatory treatment in the last month,
- Mother tongue other than French,
- Psychotic episode due to an organic disorder,
- Psychotic episode induced by the use or withdrawal of toxic substances with severe dependence ,
- Intellectual deficit,
- Chronic inflammatory disease,
- Immunomodulatory treatment,
- Contraindication to MRI,
- Pregnant or breastfeeding woman,
- Patient under court protection, guardianship, curatorship or deprived of liberty.
Key Trial Info
Start Date :
March 27 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2030
Estimated Enrollment :
217 Patients enrolled
Trial Details
Trial ID
NCT05384392
Start Date
March 27 2025
End Date
March 1 2030
Last Update
September 12 2025
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr Bénédicte GOHIER
Angers, France, 49033
2
Dr Florian STEPHAN
Brest, France, 29609
3
Dr Anne SAUVAGET
Nantes, France, 44093
4
Dr Sonia MARSELLA
Quimper, France, 29017